RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea
RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.
The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."
RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.
RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.